Published in Nat Rev Gastroenterol Hepatol on February 02, 2010
Duodenal implications in the pathophysiology of functional dyspepsia. J Neurogastroenterol Motil (2010) 0.99
CD34 is required for infiltration of eosinophils into the colon and pathology associated with DSS-induced ulcerative colitis. Am J Pathol (2010) 0.95
Therapeutic concepts in adult and paediatric eosinophilic oesophagitis. Nat Rev Gastroenterol Hepatol (2012) 0.94
The pan-B cell marker CD22 is expressed on gastrointestinal eosinophils and negatively regulates tissue eosinophilia. J Immunol (2011) 0.94
Functional dyspepsia: new insights into pathogenesis and therapy. Korean J Intern Med (2016) 0.92
Analysis of Gastric and Duodenal Eosinophils in Children with Abdominal Pain Related Functional Gastrointestinal Disorders According to Rome III Criteria. J Neurogastroenterol Motil (2016) 0.89
Eosinophilic Gastroenteritis: Case Report and Review in Search for Diagnostic Key Points. Case Rep Gastrointest Med (2015) 0.87
Human eosinophils express RAGE, produce RAGE ligands, exhibit PKC-delta phosphorylation and enhanced viability in response to the RAGE ligand, S100B. Int Immunol (2011) 0.87
Impact of microscopic duodenitis on symptomatic response to Helicobacter pylori eradication in functional dyspepsia. Dig Dis Sci (2014) 0.85
Heterogeneity across the murine small and large intestine. World J Gastroenterol (2014) 0.83
Recurrent blood eosinophilia in ulcerative colitis is associated with severe disease and primary sclerosing cholangitis. Dig Dis Sci (2012) 0.80
Selective IgA deficiency mimicking Churg-Strauss syndrome and hypereosinophilic syndrome: a case report. Nagoya J Med Sci (2013) 0.76
Elements Involved In Promoting Eosinophilic Gastrointestinal Disorders. J Genet Syndr Gene Ther (2015) 0.76
Evaluation of Helicobacter pylori eradication and drug therapy in patients with functional dyspepsia. Exp Ther Med (2013) 0.75
Eosinophils may play regionally disparate roles in influencing IgA(+) plasma cell numbers during large and small intestinal inflammation. BMC Immunol (2016) 0.75
Myenteric plexitis: A frequent feature in patients undergoing surgery for colonic diverticular disease. United European Gastroenterol J (2015) 0.75
Idiopathic focal eosinophilic enteritis (IFEE), an emerging cause of abdominal pain in horses: the effect of age, time and geographical location on risk. PLoS One (2014) 0.75
The mucosal immune system: master regulator of bidirectional gut-brain communications. Nat Rev Gastroenterol Hepatol (2017) 0.75
Established and Emerging Eosinophilic Gastrointestinal Diseases (EGIDs): Seeing Red and Looking Ahead. Dig Dis Sci (2016) 0.75
Functional bowel disorders. Gastroenterology (2006) 20.72
Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology (2007) 9.05
Leukocyte-endothelial adhesion molecules. Blood (1994) 8.62
Eosinophilic inflammation in asthma. N Engl J Med (1990) 8.05
The eosinophil. Annu Rev Immunol (2006) 7.06
Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology (2002) 5.50
Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest (2006) 5.48
Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology (1998) 5.34
The prevalence of food allergy: a meta-analysis. J Allergy Clin Immunol (2007) 5.16
Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med (2008) 4.93
Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol (2004) 4.69
The idiopathic hypereosinophilic syndrome. Blood (1994) 4.65
Eosinophilic gastroenteritis: a clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues. Gut (1990) 4.60
A population study of food intolerance. Lancet (1994) 4.54
Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology (2004) 4.05
Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol (2006) 3.51
Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor. J Exp Med (1988) 3.50
Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology (2000) 3.49
Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol (2006) 3.30
Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med (1990) 3.29
Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology (2002) 3.11
Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood (1989) 3.10
Variability in diagnostic criteria for eosinophilic esophagitis: a systematic review. Am J Gastroenterol (2007) 2.94
A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med (2006) 2.94
Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol (1991) 2.88
Transforming growth factor beta: the good, the bad, and the ugly. J Exp Med (1994) 2.86
Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med (1995) 2.83
Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut (2008) 2.77
Churg-Strauss syndrome. Lancet (2003) 2.74
Dyspepsia in England and Scotland. Gut (1990) 2.73
Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J Exp Med (1988) 2.71
Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol (2001) 2.62
Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut (2010) 2.47
Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol (2007) 2.44
Immunohistochemical study of intestinal eosinophils in inflammatory bowel disease. J Clin Gastroenterol (2003) 2.36
T cells and eosinophils in the pathogenesis of asthma. Immunol Today (1992) 2.30
The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. Proc Natl Acad Sci U S A (2002) 2.24
Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil (2000) 2.16
The role of eosinophils in host defense against helminth parasites. J Allergy Clin Immunol (2004) 2.13
Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut (2007) 2.11
The association between gastro-oesophageal reflux disease and asthma: a systematic review. Gut (2007) 2.10
Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest (1999) 2.05
Eotaxin is required for the baseline level of tissue eosinophils. Proc Natl Acad Sci U S A (1998) 1.98
IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against "intrinsic" asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med (1996) 1.93
Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: the population-based Kalixanda study. Gut (2006) 1.92
Activated T cells and eosinophilia in bronchoalveolar lavages from subjects with asthma correlated with disease severity. J Allergy Clin Immunol (1991) 1.92
Eosinophilic esophagitis in adults: distinguishing features from gastroesophageal reflux disease: a study of 41 patients. Mod Pathol (2006) 1.89
Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol (2009) 1.88
Mechanisms underlying the maintenance of muscle hypercontractility in a model of postinfective gut dysfunction. Gastroenterology (2005) 1.86
Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci (1993) 1.83
Gastrointestinal symptoms in patients with asthma. Arch Dis Child (2000) 1.82
Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology (1986) 1.79
Intraepithelial eosinophils: a new diagnostic criterion for reflux esophagitis. Gastroenterology (1982) 1.73
Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis. Gastroenterology (1996) 1.73
Activation of basophil and mast cell histamine release by eosinophil granule major basic protein. J Exp Med (1983) 1.69
Human milk-specific mucosal lymphocytes of the gastrointestinal tract display a TH2 cytokine profile. J Allergy Clin Immunol (2002) 1.67
Eosinophilic gastroenteritis associated with systemic lupus erythematosus. J Clin Gastroenterol (2004) 1.67
Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol (1989) 1.64
Eosinophilic gastroenteritis with esophageal involvement. Gastroenterology (1977) 1.62
Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut (2006) 1.60
Eosinophilic esophagitis: pathogenesis, genetics, and therapy. J Allergy Clin Immunol (2006) 1.60
Eosinophil infiltration and degranulation in normal human tissue. Anat Rec (1998) 1.59
Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol (1997) 1.59
A pathological function for eotaxin and eosinophils in eosinophilic gastrointestinal inflammation. Nat Immunol (2001) 1.58
Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology (1996) 1.53
Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. J Clin Invest (1993) 1.53
Eosinophils can function as antigen-presenting cells to induce primary and secondary immune responses to Strongyloides stercoralis. Infect Immun (2006) 1.53
CD4+ cells proliferate after peanut-extract-specific and CD8+ cells proliferate after polyclonal stimulation of PBMC of children with atopic dermatitis. Clin Exp Allergy (1998) 1.46
Quantity and distribution of eosinophils in the gastrointestinal tract of children. Pediatr Dev Pathol (2006) 1.44
Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol (2006) 1.43
Visceral hypersensitivity: facts, speculations, and challenges. Gut (2001) 1.42
Eosinophils in the rectal mucosa. A simple method of predicting the outcome of ulcerative proctocolitis? Gut (1979) 1.28
Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther (2009) 1.28
Eosinophilic myenteric ganglionitis is associated with functional intestinal obstruction. Gut (2003) 1.27
Eosinophil infiltration of the oesophageal mucosa in patients with pollen allergy during the season. Clin Exp Allergy (2005) 1.26
Intracellular signaling mechanisms regulating toll-like receptor-mediated activation of eosinophils. Am J Respir Cell Mol Biol (2007) 1.26
Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut (2008) 1.24
Immunoreactivity for interleukin 3 and 5 and granulocyte/macrophage colony-stimulating factor of intestinal mucosa in bronchial asthma. J Exp Med (1995) 1.22
Intestinal permeability test as a predictor of clinical course in Crohn's disease. Am J Gastroenterol (1999) 1.22
Eosinophils from granulomas in murine schistosomiasis mansoni produce substance P. J Immunol (1988) 1.21
Marked deposition of eosinophil-derived neurotoxin in adult patients with eosinophilic esophagitis. Am J Gastroenterol (2009) 1.21
Eosinophils function as antigen-presenting cells. J Leukoc Biol (2004) 1.20
Effects of IL-5, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosinophils in vitro. Clin Exp Immunol (1991) 1.19
Eosinophil-associated gastrointestinal disorders: a world-wide-web based registry. J Pediatr (2002) 1.17
Cytokine expression in healthy and inflamed mucosa: probing the role of eosinophils in the digestive tract. Inflamm Bowel Dis (2005) 1.14
Eosinophil activation in ulcerative colitis: studies on mucosal release and localization of eosinophil granule constituents. Dig Dis Sci (1998) 1.12
Increased intestinal permeability in bronchial asthma. J Allergy Clin Immunol (1996) 1.11
Tissue eosinophils in ulcerative colitis. Scand J Gastroenterol (1979) 1.10
Increased prevalence of irritable bowel syndrome in patients with bronchial asthma. Respir Med (2003) 1.07
Esophageal histology in gastroesophageal reflux. Morphometric findings in suction biopsies. Am J Dig Dis (1977) 1.06
Observations on possible immunity to reinfection among Kenyan schoolchildren after treatment for Schistosoma mansoni. Trans R Soc Trop Med Hyg (1983) 1.05
Increased prevalence of gastrointestinal symptoms in patients with allergic disease. Postgrad Med J (2007) 1.04
Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion. Am J Gastroenterol (1999) 1.04
Natural history of dyspepsia. Gut (2002) 1.03
Eosinophil granulocytes are activated during the remission phase of ulcerative colitis. Gut (2005) 1.03
Danger signals derived from stressed and necrotic epithelial cells activate human eosinophils. Immunology (2004) 1.01
ICAM-1-dependent pathways regulate colonic eosinophilic inflammation. J Leukoc Biol (2006) 1.01
Eosinophilia and resistance to Schistosoma haematobium in man. Parasite Immunol (1985) 1.00
Functional gastroduodenal disorders. Gastroenterology (2006) 8.51
Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology (2005) 5.77
The Oslo definitions for coeliac disease and related terms. Gut (2012) 5.76
Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol (2007) 4.14
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ (2008) 4.12
An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol (2009) 3.99
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 3.97
Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol (2009) 3.88
Functional Dyspepsia. N Engl J Med (2015) 3.66
Psychosocial factors are linked to functional gastrointestinal disorders: a population based nested case-control study. Am J Gastroenterol (2004) 3.11
Gastro-oesophageal reflux disease. Lancet (2006) 2.96
A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med (2006) 2.94
Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA (2008) 2.89
An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol (2003) 2.83
Immune activation in patients with irritable bowel syndrome. Gastroenterology (2007) 2.82
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol (2005) 2.68
Mouse DNA contamination in human tissue tested for XMRV. Retrovirology (2010) 2.65
The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology (2004) 2.59
Design of treatment trials for functional gastrointestinal disorders. Gastroenterology (2006) 2.58
Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol (2005) 2.56
Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol (2009) 2.55
Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology (2006) 2.46
Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol (2007) 2.44
Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol (2008) 2.28
G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology (2004) 2.24
Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol (2006) 2.21
Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study. Gastroenterology (2009) 2.19
Association between constipation and colorectal cancer: systematic review and meta-analysis of observational studies. Am J Gastroenterol (2013) 2.18
Prevalence and predictive factors of eosinophilic esophagitis in patients presenting with dysphagia: a prospective study. Am J Gastroenterol (2007) 2.14
Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology (2007) 2.14
High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol (2005) 2.13
Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol (2012) 2.09
Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 2.04
Risks of proton-pump inhibitors: what every doctor should know. Med J Aust (2009) 2.03
Detection of celiac disease and lymphocytic enteropathy by parallel serology and histopathology in a population-based study. Gastroenterology (2010) 2.01
Does Helicobacter pylori really cause duodenal ulcers? Yes. BMJ (2009) 2.01
Prevalence of faecal incontinence and associated risk factors; an underdiagnosed problem in the Australian community? Med J Aust (2002) 2.00
Variation in prevalence, diagnostic criteria, and initial management options for eosinophilic gastrointestinal diseases in the United States. J Pediatr Gastroenterol Nutr (2011) 1.96
A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology (2002) 1.94
Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: the population-based Kalixanda study. Gut (2006) 1.92
The epidemiology of childhood recurrent abdominal pain in Western countries: a systematic review. Am J Gastroenterol (2005) 1.90
Diarrhea-predominant irritable bowel syndrome is associated with diverticular disease: a population-based study. Am J Gastroenterol (2009) 1.88
Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms. Qual Life Res (2004) 1.88
Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol (2004) 1.86
Systematic review on the management of chronic constipation in North America. Am J Gastroenterol (2005) 1.85
Celiac disease serology in irritable bowel syndrome and dyspepsia: a population-based case-control study. Mayo Clin Proc (2004) 1.85
Diet and functional gastrointestinal disorders: a population-based case-control study. Am J Gastroenterol (2005) 1.84
Gastrointestinal symptoms and glycemic control in diabetes mellitus: a longitudinal population study. Eur J Gastroenterol Hepatol (2008) 1.78
The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology (2008) 1.77
Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med (2004) 1.72
Epidemiology and health care seeking in the functional GI disorders: a population-based study. Am J Gastroenterol (2002) 1.70
Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol (2009) 1.67
The management of gastric polyps. Gut (2010) 1.65
Functional dyspepsia impacts absenteeism and direct and indirect costs. Clin Gastroenterol Hepatol (2010) 1.65
Peptic ulcer disease in a general adult population: the Kalixanda study: a random population-based study. Am J Epidemiol (2006) 1.64
Subsite-specific risk factors for esophageal and gastric adenocarcinoma. Am J Gastroenterol (2007) 1.63
Increased incidence and impact of upper and lower gastrointestinal events in patients with rheumatoid arthritis in Olmsted County, Minnesota: a longitudinal population-based study. J Rheumatol (2012) 1.62
Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.60
American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology (2005) 1.60
Gluten-free diet and steroid treatment are effective therapy for most patients with collagenous sprue. Clin Gastroenterol Hepatol (2010) 1.58
Endoscopic "no hole" full-thickness biopsy of the stomach to detect myenteric ganglia. Gastrointest Endosc (2008) 1.55
Clinical value of duodenal biopsies--beyond the diagnosis of coeliac disease. Pathol Res Pract (2011) 1.55
Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol (2007) 1.54
Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med (2009) 1.53
GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. Am J Gastroenterol (2002) 1.53
Screening for celiac disease in a North American population: sequential serology and gastrointestinal symptoms. Am J Gastroenterol (2011) 1.52
Can the clinical history distinguish between organic and functional dyspepsia? JAMA (2006) 1.51
5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol (2010) 1.50
A randomized, double-blind, placebo-controlled trial of St John's wort for treating irritable bowel syndrome. Am J Gastroenterol (2009) 1.47
Psychosocial distress and somatic symptoms in community subjects with irritable bowel syndrome: a psychological component is the rule. Am J Gastroenterol (2009) 1.46
Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am (2005) 1.44
Evaluation of endoscopic approaches for deep gastric-muscle-wall biopsies: what works? Gastrointest Endosc (2007) 1.44
Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol (2005) 1.44
Functional dyspepsia--symptoms, definitions and validity of the Rome III criteria. Nat Rev Gastroenterol Hepatol (2013) 1.42
Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Mol Cell Biol (2005) 1.42
Acid-suppressive therapy with esomeprazole for relief of unexplained chest pain in primary care: a randomized, double-blind, placebo-controlled trial. Am J Gastroenterol (2012) 1.40
The HIPAA authorization form and effects on survey response rates, nonresponse bias, and data quality: a randomized community study. Med Care (2007) 1.37
Is there an association between GNbeta3-C825T genotype and lower functional gastrointestinal disorders? Gastroenterology (2006) 1.35
Sodium channel mutation in irritable bowel syndrome: evidence for an ion channelopathy. Am J Physiol Gastrointest Liver Physiol (2008) 1.33
Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am J Gastroenterol (2011) 1.32
Do distinct dyspepsia subgroups exist in the community? A population-based study. Am J Gastroenterol (2007) 1.30
Diet, food intake, and disturbed physiology in the pathogenesis of symptoms in functional dyspepsia. Am J Gastroenterol (2004) 1.27
Cross-cultural development and validation of a patient self-administered questionnaire to assess quality of life in upper gastrointestinal disorders: the PAGI-QOL. Qual Life Res (2004) 1.26
Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol (2011) 1.26
A negative Helicobacter pylori serology test is more reliable for exclusion of premalignant gastric conditions than a negative test for current H. pylori infection: a report on histology and H. pylori detection in the general adult population. Scand J Gastroenterol (2005) 1.26
Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 1.24
Marked deposition of eosinophil-derived neurotoxin in adult patients with eosinophilic esophagitis. Am J Gastroenterol (2009) 1.21
Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype. Eur J Gastroenterol Hepatol (2003) 1.20
Behavioral intervention for the treatment of obesity: strategies and effectiveness data. Am J Gastroenterol (2007) 1.20
Health Insurance Portability and Accountability Act (HIPAA) authorization and survey nonresponse bias. Med Care (2011) 1.19
Can symptoms predict endoscopic findings in GERD? Gastrointest Endosc (2003) 1.19
Impact of functional gastrointestinal disorders on survival in the community. Am J Gastroenterol (2010) 1.18
Measuring successful treatment of irritable bowel syndrome: is "satisfactory relief " enough? Am J Gastroenterol (2006) 1.18
The irritable bowel syndrome has origins in the childhood socioeconomic environment. Am J Gastroenterol (2004) 1.18
Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol Cancer (2010) 1.18
Functional dyspepsia is associated with a greater symptomatic response to fat but not carbohydrate, increased fasting and postprandial CCK, and diminished PYY. Am J Gastroenterol (2008) 1.17
A history of abuse in community subjects with irritable bowel syndrome and functional dyspepsia: the role of other psychosocial variables. Digestion (2005) 1.16
A randomized controlled trial of cognitive behavior therapy, relaxation training, and routine clinical care for the irritable bowel syndrome. Am J Gastroenterol (2003) 1.16